Benefits of BioAngels Membership

  • Develop South Australian and Australian economies. BioAngels actively support and mentor entrepreneurs and help young and innovative companies grow locally, across Australia and worldwide.
  • Supporting and investing locally has led to the formation of successful start-up ecosystems across the country, developing talent, innovation and local economies.
  • Due diligence helps start-up CEO, Founders and Inventors improve their business model which prepares them for domestic and global markets.
  • Calculated risk lowers investment risk which ensures that funding goes to an investment ready business.
  • Increase scope and potential to diversify your investment portfolio while reducing risk of investment losses.
  • Remain up to date on new ideas, technology and invocation emerging industries and markets.
  • Work together, network and have fun with like-minded group of successful entrepreneurs and executives.
  • Learn new investment skills from other members and improve results due to investing collectively.
  • Pooling individual capital increases the chance that entrepreneurs can attract enough money to build their businesses.
  • Connections to a co-investment eco-system, so that portfolio firms have a better chance for growth capital.
  • Introductions and access to the BioAngels local and international networks.
  • Increased deal flow to top emerging companies across a broad range of segments – quality and quantity
  • Collaboration and syndicating with other Angel groups in Australia and Worldwide.


BioAngels would like to hear from you if you are interested in becoming a member.

To contact the Executive Officer, email

Alan Irving

Dr Alan Irving holds degrees in Veterinary Science and a Masters in Business Administration. He is a director of the Adelaide Northern Veterinary Group and has previously been involved with bovine embryo transplant technology, an intensive quarantine piggery and export of hay to Japan. Additional business experience has been gained from ownership of a cattle station in western Queensland and an aviation charter business. Throughout his varied career, Dr Irving has always been interested in Small Business Entrepreneurship.

Corinna Steeb

Corinna Steeb is a co-founder and Executive Director at the Prancing Pony Brewery, a boutique, craft brewery located in the Adelaide Hills with a unique point of difference. The Prancing Pony has a great range of craft beers and has achieved significant market penetration and distribution of the beer range through 500 outlets in Australia.

Prior to joining the Prancing Pony Brewery full time, Corinna as the founder and Managing Director of Rubys Creative Business Solutions has assisted and numerous companies with growth and start up strategies

Industry sectors include Life Sciences, Technology, Food & Beverage, Tourism, Pharmaceuticals & Neutraceuticals, Cosmetics and Engineering & Manufacturing. Trained in Sciences and passionate about Business, Corinna’s core competencies are Business development, Strategy, Marketing, Project Management and Start-ups.

Darren Oemcke

I enjoy working in businesses, developing businesses, advising business and government and growing businesses a consultant, director or mentor. I have a very strong background and interest in R&D implementation / commercialisation, product development, management of complex projects and developing and modernising businesses.

My background includes CEO of Provisor, which had a strong focus on R&D implementation and product development, R&D Manager at United Water, management consulting, project management, engineering consulting, and research engineer. I have broad industry experience including water, wine, mining, food, beverages, clothing, health, manufacturing, environment, shipping, education and tourism.

He is currently:

  • Director and Consultant, Hydraco Pty Ltd: Business modernisation, operational improvement, start-ups, product development, R&D implementation, re-engineering, collaborative contracting, project management
  • Director/co-founder, Bowerbase Pty Ltd: ‘Thin-slice’ app developer with tools in knowledge capture, sales coaching, call management and locationally-tagged EHS risk documentation
  • Director/co-founder, Invina: High-end wine tourism Chair, Surfing South Australia
  • Director, Wine Industry Suppliers Australia

I also train consultants as a facilitator for NVI/Flinders University in Flinders Enterprise Consulting and managers as a facilitator for the Australian Institute of Management.

I have been a director of the CRC Water Quality and Treatment, on the TAG of the Reef Research CRC, director/CEO of an MNRF, director of the Centre for Groundwater Studies (and Chair of the Commercialisation committee), Chair of the Australian Science and Math School, a member of the SA Premiers Wine Council and an Adjunct Senior Lecturer of Chemical Engineering at Adelaide University.

I have post-graduate qualifications in engineering and management, and have undertaken study in leadership, disruptive innovation and teaching and am a graduate of the Australian Institute of Company Directors.

David Saint (Chairman)

David Saint is an Associate Professor in the School of Molecular and Biomedical Sciences at the University of Adelaide, researching cardiovascular disease. He holds a PhD in Physiology and Pharmacology and has published over 60 research papers. In 2003 he obtained an MBA from the University of Adelaide. From 1987 to 1995, he was a Research Fellow at the John Curtin School of Medical Research in Canberra. He also worked as a toxicologist with the TGA in 1995/6 before moving to Adelaide in 1997. David has been the national secretary of the International Society for Heart Research and is a member of the NHMRC grant review panel (Pharmacology). David was the CEO and co-founder of Rhinopharma Ltd., now re-listed as Verona Pharmaceuticals on the AIM exchange in London.

Greg Eaton

Over 35 years’ experience as management consultant, technologist, corporate re-engineering practitioner (restructuring), innovator, business mentor, strategist, negotiator, business manager, commercialisation expert, board adviser and company director.

Self-employed since 1976, (and prior) Greg has been founding director of many start-ups here and in Germany. Greg has also been a director and CEO of several public companies, here, in NZ and in the USA. These include Genetics, Pharmaceutical and Phytochemistry public companies.

Greg was an active member of the curriculum advisory committee of the then fledgling Griffith University, The Research and IP Committee of the Centre for Molecular Genetics at UWA, The Immunogenetics Research Foundation at Royal Perth Hospital and was a ministerial appointment to the Tax Concession Committee of the Federal IR&D Board, as well as serving on several Australian Standards committees for over twenty years.

In the early seventies, Greg ran the tissue culture laboratory at UofQ Biochemistry Department and later worked as a technician on the transplant research team at Royal Brisbane Hospital – both NHMRC grant appointments.

Greg has many patents and devices to his credit including IVD devices, other medical devices, micro-fluidics, and chemistry (including insecticides) and was Inventor of The Year for “Safety Mains Switches” and has won two Australian Design Awards, amongst other awards. Greg currently continues his consultancy, mentors several companies pro-bono and is also busy establishing a private equity venture fund.

Herve Astier (TechInSA Representative)

Herve is Business Development Manager, TechInSA. In 2001, the State Government established BioSA to foster the growth of the South Australian bioscience industry. In 2016 BioSA’s regulations were renewed and expanded and the organisation became TechInSA. TechInSA is dedicated to providing world-class infrastructure, high-level business advice and expertise, financial assistance, marketing and communication services to support the growth of the thriving high-tech industry in South Australia. TechInSA is committed to promoting and accelerating the commercialisation of R&D in South Australia.

Hugo LeMessurier

Hugo has held directorships and senior management positions in start-up, listed and multinational organisations in the USA, EU and Australia. He has founded and directed a number of private and listed Australian companies in the food, service and biotechnology industries. As Managing Director of LeMessurier Solutions, he has assisted the building of sustainable SME businesses via strategic planning, sales and marketing, international business development, capital raising and public company listing. Hugo is Managing Director of LeMessurier Solutions, Director of Calpain Pty Ltd, Axxos Pty Ltd, Growth Mentor Pty Ltd, Idea Nexus Pty Ltd and Spero Potentiator Australia Pty Ltd and a member of the Australian Institute of Company Directors.

John Ballard (Secretary)

John Ballard was Managing Director and CEO of GroPep Ltd from its inception in 1988 until 2002 and guided the company to a listing on the ASX. He was one of the founders of BioAngels in 2002 and remains a Director. He also serves on the Boards of BR Angels Pty Ltd, Neubody Pty Ltd and the not-for-profit company Australian Proteome Analysis Facility Ltd of which he is Chairman. He is a biochemist by training (PhD, DSc), has authored more than 300 research publications and is an inventor of 10 patents. He was elected to the Australian Academy of Technological Sciences and Engineering in 1997.

Keith Potts

Keith Potts is an angel investor in new technology companies, consultant and a company director. He is the director and chairman of Pristine Forage Technologies and a director of Cereal Electricity Pty. Ltd. and Kyna Keju Pty. Ltd. Keith has held executive positions with the CRC CSSIP as Marketing Manager (2000 – 2004) and was a Business Development Manager with CSIRO, manufacturing, sciences and technology. He has an extensive background in project management in particular in petroleum and geophysical exploration in Australia, New Zealand, Libya, Nigeria, the UK, Mozambique and Iran. He holds formal qualifications in Applied Physics (BSc.) and has a Masters of Business Administration. He also holds a professional certificate in arbitration and mediation and is a graduate of the Australian Institute of Company Directors (GAICD). Keith’s main interests are in climate change research, renewable energy (biofuels), start-up companies, new technology, and the share market.

Leanna Read

Dr. Leanna Read is the Chief Scientist for South Australia. Other current appointments include chair of the South Australian Science Council and of the Cooperative Research Centre for Cell Therapy Manufacturing; member of the SA Economic Development Board and of the federal Biomedical Translation Fund Committee; board member of a biotechnology company; and member of Council for the University of South Australia.

Previous roles include founding Managing Director and CEO of biotechnology company, TGR BioSciences Pty Ltd as well as CEO of the Cooperative Research Centre for Tissue Growth and Repair.

Leanna’s industry and research contributions have been recognised by appointment to federal boards including the Prime Minister’s Science, Engineering and Innovation Council, the Industry R&D Board and the Future Manufacturing Industry Innovation Council.

A Fellow of the Australian Academy of Technological Sciences and Engineering and of the Australian Institute of Company Directors, Leanna has received a number of awards, including an Honorary Doctorate from the University of South Australia, the 2006 South Australian of the Year (Science and Technology), and the 2011 Central Region winner of the Ernst & Young Entrepreneur of the Year in the Technology Category.

Lee Walker-Roberts (Board Member & Executive Officer)

Lee is Founder & CEO Creative Juices, a highly specialized global advisory and commercialization firm guiding founders, inventors and executives of worldwide and Australian start-ups and SMEs across Medtech, Biotech, Life Sciences, Digital Health and related ICT, Unstructured meta data (health, finance, defence, national security and law enforcement and CRC’s), Edtech, Cleantech, Hi-tech Engineering and Manufacturing Innovation and Transformation.

An experienced, successful business leader and entrepreneur, with a proven record of growing innovative businesses in highly competitive markets, Lee has held senior executive and advisory roles in the global high-tech companies ranging from privately-owned Start-ups to PE & VC backed companies with over $200 million in annual sales. Over last 17 years, he has been directly responsible for growing and managing top line sales revenues >AUD$185M; Market and geographical expansion & commercializing new technologies across Americas, EU, Far East & APAC; Coaching executive & management teams; Cooperatively raised AUD$M’s across Angel, PE, VC investment; & Successful trade sale/exit.

Lee co-founded 4 BioTech Start-Ups. He served as President & CEO, 2003 – 2010, Director, Sales & Marketing and Advisor. An experienced stakeholder manager, he has successfully negotiated contract manufacturing, OEM, JV, Royalty & Research Agreements across multiple geographical jurisdictions. Opto Global was acquired by Optos PLC (FTSE, OPTS) for USD$10.75 Million, Dec 2010. Lee consulted to Optos PLC across 2 significant acquisitions and global channel strategies.

Lee was awarded Southern Region Finalist, Technology & Emerging Industries, EY Entrepreneur Of The Year Awards, 2008. Member Expert Network, Accelerating Commercialization, AusIndustry’s Entrepreneurs’ Infrastructure Programme. Panel Member, Commercial Accelerator Scheme (CAS), Adelaide Enterprise, University of Adelaide and Member, Innovation Bay.


Michelle Perugini

Dr Michelle Perugini is an academic, entrepreneur, and an internationally renowned expert in health, medical research, and advanced analytics technologies.

Michelle has 15 years experience in health and medical research, specialising in predictive genetics and translational medicine. Michelle was also the founder of the global technology company ISD Analytics, leading the commercialisation of its award-winning predictive analytics product Simulait, which was acquired by Ernst and Young {EV) in 2015 to become one of EY’s global suite of analytics products. She has a broad and diverse skill-set, with technical, management and business experience, and the ability to lead research and global commercial projects, with a strong track record of publications, awards, and grants in the field.

As a research scientist, Michelle led large complex research projects that translated genetic mutation analysis {bioinformatics) to clinical treatments for cancer patients. She was also the pioneer of new methods in proteomics that now drive drug discovery. Her extensive and cross-disciplinary publication record exemplifies her ability to produce quality research and communicate this effectively.

In addition to a successful medical research career, Michelle co-founded an innovative start-up in 2007 called ISD Analytics where she led the research and development, and commercialisation, of its award­ winning human-population behaviour predictive analytics software product Simulait. Michelle and her team grew ISD Analytics into a successful and global business, working with large businesses and Government clients, and with offices in Adelaide, Melbourne, and Silicon Valley. In 2015, ISD Analytics was acquired by Ernst & Young and Michelle drove the commercial integration as an Executive Director in the Advanced Analytics and Modelling function of the business. Michelle now mentors other technology start­ up companies .

Oliver Mayo

Oliver Mayo is a statistician and geneticist with special interest in plant and animal breeding and human population genetics. He is an honorary Research Fellow with CSIRO Livestock Industries, and adjunct Professor of Biometry, Faculty of Sciences, University of Adelaide. He has a particular interest in the commercialisation of IP from large public sector institutions.

Robert Rush

Robert Rush is a Professor Emeritus in the Department of Human Physiology, School of Medicine at Flinders University. Professor Rush has a PhD in Physiology from Monash University and has held positions in a number of Universities and Institutes around the world including the University of California, San Diego, McGill and Cambridge Universities. He has published over 150 manuscripts in leading scientific journals, written numerous chapters in specialised texts and edited two books. In 1998, he founded Neubody Pty. Ltd., an emerging company focused on antibody technologies and he now acts as the chairman of both Neubody and subsidiary, Biosensis Pty Ltd. Professor Rush has also held positions as a Director of Neurosciences Australia, Inc., and is an independent director on the board of the CRC for Diagnostics.

Rod Cooter

Rod Cooter is a plastic surgeon from Adelaide. He trained in Australia and the UK and completed a research doctorate before commencing plastic surgery.  He is a past national president of the Australian Society of Plastic Surgeons and is clinical lead for the new Australian Breast Device Registry. He is an adjunct clinical professor in Monash University’s Department of Epidemiology and Preventive Medicine. He has formed an international collaboration of breast registry activities, known as ICOBRA, which involves 15 other countries’ plastic surgery societies. Rod brings an insight into medical devices and applications as well as research and product development.

Tim Hirst

Tim is an entrepreneurial academic with wide-ranging experience in establishing new venture-backed companies. He has held Senior Executive positions in universities in the United Kingdom and Australia and been a non-executive director of biotech, material science and IT companies, as well as innovation incubators and major national research facilities. He was Professor and Head of Microbiology at the University of Bristol, UK; Deputy Vice Chancellor (Research & Innovation) at the University of Sydney and CEO of ANU Connect Ventures – a $30M pre-seed investment fund established by the Australian National University and MTAA Super. Currently, he is the Executive Chairman of Gamma Vaccines – a company developing improved respiratory vaccines against pneumococcal disease and avian & human influenza viruses. He is also Chairman of OzStar Therapeutics a clinical stage company developing an add-on therapy for treating patients with Type 2 diabetes and is Honorary Adjunct Professor in the School of Biological Sciences at the University of Adelaide and the School of Life Sciences at the Institute of Technology in Bandung, Indonesia.

Tim Lovell

Tim is the Co-founder, President and CEO of Calpain Therapeutics, a privately-funded ophthalmology biopharma company created to commercialise novel pharmaceutical technology to treat diseases associated with front and back of the eye.

Tim is also the Co-founder of a privately-held mobile IT/software operation, currently in stealth mode, and created to produce leapfrog products that will forever change professional and personal networking for the better.

Tim is the Director of ITBioCo, a privately-held company that specialises in investing in publicly-listed Life Science/Healthcare and Mobile IT and software investments.

Prior to the above current positions, Tim was the founder, President and CEO of Viewsoft, a privately-held mobile IT/software company that specialised in producing interactive 3D documents for educational and advertising purposes.

Tim was also the Director of New Ventures for Surgical Research Australia – a veterinary surgical practice, a Business Development Manager at Bio Innovation SA – an investment and granting authority covering biotechnology, pharmaceuticals and healthcare that worked closely with local venture capital providers, and an external consultant for a state-of-the-art California software company.

Tim is an experienced entrepreneur, responsible for providing business advice and assistance to start-up biotechnology and biopharma companies, medical device companies, diagnostic companies, digital health companies, Mobile App, and IT and software companies, and universities in business strategy, company formation, commercialisation, product design, product development, business strategy, business model development, intellectual property protection, and sourcing, pitching and raising of finance from both the buy and the sell sides. He has successfully identified and licensed technologies, helped to form start-up companies operating across multiple fields and has raised finance in support of them, both for others and for himself as a founder.

Tim has authored numerous publications, he is an invited and accomplished speaker, and an internationally-renowned molecular modeller through twelve years spent in the pharmaceutical and not-for-profit biotech sectors. He has been active internationally in the business of science and science-related IT in the UK, Australia, Japan, Sweden, and the USA, in the development of strategic alliances and external partnering, and in the application of state-of-the-art enabling technology from a former position in the pharmaceutical industry with AstraZeneca, PLC, where he was involved in drug development and leading medicinal chemistry teams across several therapeutic areas.

Tim holds a Ph.D. in Quantum Chemistry/Theoretical Physics and Computational Molecular Modelling, an MBA specialising in entrepreneurial ventures, is a graduate of the Australian Institute of Company Directors, a member of BioAngels, a start-up competition judge, and was one of the outstanding post-Docs at the internationally-renowned Scripps Research Institute in La Jolla, California.

Domain Expertise: Life sciences and healthcare. Mobile applications and IT-software.

Tony Romagnino

In 2005, Tony moved to Sydney from Montreal, Canada where he joined the technology transfer arm of the University of New South Wales (UNSW). His experience at UNSW, his work with the Uniseed’s Venture Capital Fund, and his passion for innovation and research led him to create TM Ventures (TMV+). TMV+’s business model focuses on the early assessment and commercial validation of new technologies and products for both investors and researchers.

TMV+ is also a continuation of Tony’s past work in North America where he specialized in the Canadian consumer goods industry, the US Healthcare and Animal Health markets. His experience in manufacturing, distribution and marketing enabled him to build relationships at every level of the US Pharmaceutical supply chain and his involvement in every stage of product commercialisation, both on the human and animal side, has given him a unique perspective into the North American marketplace.

TMV+’s client base have included private and listed companies, research Institutes and universities. They vary from large multinational companies like GlaxoSmithKline, to mid-size Australian-based pharmaceutical manufacturers like Phebra, to high profile institutes like the Peter MacCallum Cancer Centre and to start ups like Australia’s newest personalised medicine company, Clarity Pharmaceuticals.

Over his career, Tony has overseen or managed over a dozen start-ups, licensed deals worth over $50 million, and managed over $2 billion of product distribution. This experience gives him a unique perspective into regional markets and the potential for innovation globally.

While based in Sydney, Australia, Tony is currently splitting his time between Australia and North America where he is focused on launching niche, Australian-made pharmaceuticals and laying the foundation for late stage drug development in the US and Canada.